Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551165 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL111167 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL1551796 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL1551168 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL4148362 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| Acetic Acid SCHEMBL15140949 | 0.96 | SLC18A3 (0.42) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL15187679 | 0.96 | CHRM2 (0.43) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL29155391 | 0.87 | MAPT (0.43) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL1472615 | 0.86 | EPHX1 (0.35) | SERPINE1CYP19A1NPY1RNPY2RNPY4R | |
| SCHEMBL29446936 | 0.84 | SLC18A3 (0.36) | SLC18A3CHRM2CHRM1CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507352-A1 | PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION | Symrise AG (DE) | 2019-07-10 | — | — | EP | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| WO-2018041354-A1 | PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION | SYMRISE AG (DE) | 2018-03-08 | — | — | WO | claimed |
| EP-2211829-B1 | IMPROVEMENT OF THE FRAGRANCE EFFECT OF PERFUME ESTERS | HENKEL AG & CO KGAA (DE) | 2011-04-27 | — | — | EP | claimed |
| US-20100210496-A1 | Fragrance Effect of Perfume Esters | BESSLER CORNELIUS | 2010-08-19 | — | — | US | claimed |
| EP-1345875-B1 | METHOD FOR PRODUCING CIS-2-TERT-BUTYLCYCLOHEXANOL BY CATALYTICALLY HYDROGENATING 2-TERT-BUTYLPHENOL | SYMRISE GMBH & CO KG (DE) | 2005-04-20 | — | — | EP | claimed |
| WO-2026046686-A1 | EVAPORATING MICROEMULSIONS | SYMRISE AG (DE) | 2026-03-05 | — | — | WO | disclosed |
| WO-2026046506-A1 | EVAPORATING MICROEMULSIONS | SYMRISE AG (DE) | 2026-03-05 | — | — | WO | disclosed |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2026-02-19 | — | — | US | disclosed |
| US-20250388749-A1 | THERMOPLASTIC POLYURETHANE (TPU) COMPOSITION WITH IMPROVED PROPERTIES | BASF SE (DE) | 2025-12-25 | — | — | US | disclosed |
| EP-4623057-A1 | ENCAPSULATED FRAGRANCE COMPOSITIONS FOR PROVIDING, MODULATING OR INTENSIFYING A SCENT | Symrise AG (DE) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025119505-A1 | ENCAPSULATED FRAGRANCE COMPOSITIONS FOR PROVIDING, MODULATING OR INTENSIFYING A SCENT | SYMRISE AG (DE) | 2025-06-12 | — | — | WO | disclosed |
| EP-4543953-A1 | THERMOPLASTIC POLYURETHANE (TPU) COMPOSITION WITH IMPROVED PROPERTIES | BASF SE (DE) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024002869-A1 | THERMOPLASTIC POLYURETHANE (TPU) COMPOSITION WITH IMPROVED PROPERTIES | BASF SE (DE) | 2024-01-04 | — | — | WO | disclosed |
| US-11603506-B2 | Product comprising a plastic container and a substance composition | SYMRISE AG (DE) | 2023-03-14 | — | — | US | disclosed |
| US-20190225396-A1 | PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION | SYMRISE AG (DE) | 2019-07-25 | — | — | US | disclosed |
| US-20190225396-A1 | PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION | SYMRISE AG (DE) | 2019-07-25 | — | — | US | disclosed |
| EP-3507352-A1 | PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION | Symrise AG (DE) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018041354-A1 | PRODUCT COMPRISING A PLASTIC CONTAINER AND A SUBSTANCE COMPOSITION | SYMRISE AG (DE) | 2018-03-08 | — | — | WO | disclosed |
| US-20100210496-A1 | Fragrance Effect of Perfume Esters | BESSLER CORNELIUS | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388749-A1 | THERMOPLASTIC POLYURETHANE (TPU) COMPOSITION WITH IMPROVED PROPERTIES | P2RY11, P2RY12, P2RY6 | SLC18A3 4336/4885CHRM2 3192/4885CHRM1 2970/4885 |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | RBP4, LRAT, RARB | SLC18A3 2590/4885CHRM2 1752/4885CHRM1 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.